BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Real-time Borsa Italiana 15:44:50 21/05/2024 BST | ||
| 3.6 EUR | +12.50% |
|
| Current month | +0.31% | ||
| 1 month | +57.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 21/05/24 | 3.6 | +12.50% |
| 20/05/24 | 3.2 | -1.84% |
| 17/05/24 | 3.26 | -1.51% |
| 16/05/24 | 3.31 | -0.60% |
| 15/05/24 | 3.33 | -4.58% |
Real-time Borsa Italiana
Last update May 21, 2024 at 03:44 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| S34620 | |
| ISIN | DE000SW7RC27 |
| Date issued | 18/03/2024 |
| Strike | 9,369 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.64 € |
|---|---|
| Lowest since issue | 1.158 € |
| Spread | 0.01 € |
| Spread % | 0.28% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
168.1
USD
Spread / Average Target
+9.41%
- Stock Market
- Certificates
- S34620 Certificat
